The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

AMX0114 is an investigational antisense oligonucleotide targeting calpain-2, a calcium-activated protease believed to play a role in ALS disease progression. The Food and Drug Administration (FDA) has ...

Please provide your email address to receive an email when new articles are posted on . AMX0114 was developed to target calpain-2, a driver of axonal neurodegeneration. A pending clinical trial will ...

Eric Dane advocated for a cure for Amyotrophic Lateral Sclerosis (ALS) as the progression of his symptoms was on full display in a campaign video. After the “Euphoria” actor missed the planned “Grey’s ...

Darin Nakakihara doesn’t remember much from the day that changed his life. He left the doctor’s office and walked to his car. In the driver’s seat, he looked up the disease he was just diagnosed with, ...

Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral ...